search

Active clinical trials for "Lung Diseases, Interstitial"

Results 221-230 of 454

Evaluation of a Multi-professional Breathlessness Service for Patients With Breathlessness Due to...

BreathlessnessCOPD3 more

Breathlessness is a common and distressing symptom in patients with advanced diseases like cancer, chronic obstructive pulmonary disease (COPD), chronic heart failure (CHF) or lung fibrosis, which broadly impacts on patients' quality of life and may result in high burden for carers. This single-blinded randomized controlled fast track trial evaluates the effectiveness of a multi-professional breathlessness service in patients with advanced and chronic diseases. The intervention group will get immediate access to the breathlessness service whereas the control group will receive standard care and get access to the service after a waiting time of eight weeks. Primary endpoints are mastery of breathlessness and quality of life, measured with the CRQ (Chronic Respiratory Questionnaire) as well as the reduction of symptom burden of patients and burden of carers. The evaluation of the cost effectiveness of the breathlessness service from the perspective of the German health system is a further study aim.

Completed6 enrollment criteria

Evaluation of Efficacy and Safety of Rituximab With Mycophenolate Mofetil in Patients With Interstitial...

Lung DiseaseInterstitial

The purpose of the study is to evaluate the efficacy on lung function 6 months after one course of rituximab (2 infusions) and mycophénolate mofétil (MMF) treatment compared to one course of placebo and 6 months of MMF treatment in a broad range of patients with Interstitial Lung Diseases (ILD) non-responders to a first line immunosuppressive treatment.

Completed28 enrollment criteria

Study to Compare the Efficacy of Mycophenolate Mofetil in Systemic Sclerosis Related Early Interstitial...

Systemic SclerosisScleroderma1 more

Systemic sclerosis is a multisystem disease and can involve the lungs in the form of ILD. Lung involvement is the most common cause of death in these patients. The present study is performed to study the efficacy of oral mycophenolate mofetil in treating early and mild ILD in patients of SSc. The efficacy and side effects of mycophenolate mofetil will be compared with that of oral placebo.

Completed15 enrollment criteria

Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate

SclerodermaSystemic1 more

A Phase II multi-center, double-blind, parallel group, randomized and placebo-controlled clinical trial addressing the treatment of patients with active and symptomatic Scleroderma-related interstitial lung disease (SSc-ILD).

Completed37 enrollment criteria

Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension...

Pulmonary Arterial HypertensionInterstitial Lung Disease1 more

Our hypothesis is that IV or SQ Treprostinil can improve 6 minute walk distance, hemodynamics and quality of life in patients with interstitial lung disease and severe secondary pulmonary arterial hypertension.

Completed14 enrollment criteria

Open-label Study With Bosentan in Interstitial Lung Disease

Interstitial Lung DiseaseScleroderma

This study will asses the long term safety and efficacy of oral bosentan to patients suffering from Interstitial Lung Disease.

Completed5 enrollment criteria

The Effects of Breathing Retraining in Patients With Interstitial Lung Diseases

Interstitial Lung Disease

Breathing retraining has been reported to lead to improvements in dyspnoea and walking distance in chronic obstructive pulmonary disease (COPD) patients. Evidence regarding the effects of such an intervention in ILD patients is though lacking. In view of this, the aims of such a study were to identify whether breathing retraining led to better management of dyspnoea and improved walking distance in ILD patients.

Completed5 enrollment criteria

A Trial to Evaluate the Safety of Long Term Treatment With Nintedanib in Patients With Scleroderma...

Lung DiseasesInterstitial

The main objective is to assess long term safety of treatment with oral nintedanib in patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD).

Completed34 enrollment criteria

Systemic Corticosteroids in Treatment of Post-COVID-19 Interstitial Lung Disease

Covid19COVID-19 Pneumonia1 more

Aim: To investigate the efficacy of systemic corticosteroids in treatment for Post-COVID-19 Interstitial Lung Disease. Method: Method: In this multi-centre, prospective, randomised controlled open label clinical trial, patients are divided into two arms: standard treatment arm and standard plus systemic corticosteroid arm. After twelve weeks; clinical, functional, and radiological improvement will being assessed as primary outcomes.

Completed15 enrollment criteria

Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma

SclerodermaInterstitial Lung Disease

This study evaluates if dabigatran etexilate is safe for use in patients with Scleroderma and Interstitial Lung Disease. All patients will receive 75mg of dabigatran etexilate twice a day for 6 months.

Completed36 enrollment criteria
1...222324...46

Need Help? Contact our team!


We'll reach out to this number within 24 hrs